Recent Finacing
Recent Raise
Ajax Therapeutics develops selective, structure-guided small‑molecule JAK inhibitors for myeloproliferative neoplasms, using Schrödinger-enabled computational drug design to advance AJ1‑11095 (Type II JAK2) toward clinical studies.
